The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).

Nov 29, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Explore Original Article articles from The New England Journal of Medicine

Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, …

The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed ...

Index of all Issues from New England Journal of Medicine

May 7, 2025 · Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been …

Jun 18, 2025 · The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma …

Nov 16, 2024 · Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 …